MATERIALISE NV (MTLS) Form 6-K — Oct 28, 2026
Materialise NV reported Q3 2026 revenue of EUR 67.7 million, up 2.1% year-over-year or 4.9% excluding revenue from recently divested RapidFit and Eyewear businesses. Net profit was EUR 1.4 million (EUR 0.02 per diluted share), down from EUR 1.8 million a year ago, as adjusted EBIT fell to EUR 2.5 million from EUR 2.9 million amid 11.9% higher R&D spend. Materialise Medical drove growth with 9.7% revenue growth to EUR 36.5 million, while Software revenue declined to EUR 9.9 million and Manufacturing returned to slight growth (+1.5% adjusted) with a narrower segment loss. The company reconfirmed full-year 2026 guidance of EUR 273-283 million revenue and EUR 12-14 million adjusted EBIT.
Key figures
- Eps
- 0.02
- Revenue
- 67670000
- Guidance
- Full-year 2026 revenue of 273,000-283,000 kEUR and Adjusted EBIT of 12,000-14,000 kEUR both reconfirmed
- Net Income
- 1383000
- Total Debt
- 71056000
- Revenue Yoy
- 2.1% (4.9% excluding divested Manufacturing revenue)
- Total Assets
- 429576000
- Cash Position
- 153529000
- Shares Outstanding
- 57839000
- Gross margin
- 57.7% (vs 56.8%)
- Q3 buyback k EUR
- 2277
- Buyback total k EUR
- 7482
- Free cash flow q3 k EUR
- 11419
- Medical revenue growth
- 9.7%
- Net cash position k EUR
- 82473
- Shares repurchased total
- 1426784
- Adjusted ebit q3 2025 k EUR
- 2918
- Adjusted ebit q3 2026 k EUR
- 2485
- Operating cash flow q3 k EUR
- 9666
- Adjusted ebitda q3 2025 k EUR
- 8428
- Adjusted ebitda q3 2026 k EUR
- 8046
- Medical segment revenue k EUR
- 36542
- Software segment revenue k EUR
- 9864
- Manufacturing segment revenue k EUR
- 21266
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.